Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Rand...

por Glund, Stephan, Reilly, Paul, van Ryn, Joanne, Stangier, Joachim
Publicado 2016

Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study

por Glund, Stephan, Hoefler, Josef, Lang, Benjamin, Cafiero, Stephen, Panova-Noeva, Marina, Place, Corina, Wolff, Michael
Publicado 2023

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination

por Glund, Stephan, Gan, Guanfa, Moschetti, Viktoria, Reilly, Paul, Honickel, Markus, Grottke, Oliver, Van Ryn, Joanne
Publicado 2018

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran

por Glund, Stephan, Coble, Kelly, Gansser, Dietmar, Stangier, Joachim, Hoermann, Karin, Pollack, Charles V., Reilly, Paul
Publicado 2019

Cytogenetic and FISH analyses of pancreatic carcinoma reveal breaks in 18q11 with consistent loss of 18q12-qter and frequent gain of 18p.

por Höglund, M., Gorunova, L., Jonson, T., Dawiskiba, S., Andrén-Sandberg, A., Stenman, G., Johansson, B.
Publicado 1998

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism

por Albisetti, Manuela, Schlosser, Arno, Brueckmann, Martina, Gropper, Savion, Glund, Stephan, Tartakovsky, Igor, Brandão, Leonardo R., Reilly, Paul A.
Publicado 2017

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

por Norris, Stephen, Ramael, Steven, Ikushima, Ippei, Haazen, Wouter, Harada, Akiko, Moschetti, Viktoria, Imazu, Susumu, Reilly, Paul A., Lang, Benjamin, Stangier, Joachim, Glund, Stephan
Publicado 2017

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects

por Lues, Inge, Weber, Frank, Meyer, Antje, Bühring, Uli, Hoffmann, Torsten, Kühn-Wache, Kerstin, Manhart, Susanne, Heiser, Ulrich, Pokorny, Rolf, Chiesa, Joseph, Glund, Konrad
Publicado 2015

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover P...

por Glund, Stephan, Stangier, Joachim, van Ryn, Joanne, Schmohl, Michael, Moschetti, Viktoria, Haazen, Wouter, De Smet, Marina, Gansser, Dietmar, Norris, Stephen, Lang, Benjamin, Reilly, Paul, Kreuzer, Jörg
Publicado 2016

Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)α1-specific activity and glucose transport in human skeletal muscle

por Deshmukh, A. S., Long, Y. C., de Castro Barbosa, T., Karlsson, H. K. R., Glund, S., Zavadoski, W. J., Gibbs, E. M., Koistinen, H. A., Wallberg-Henriksson, H., Zierath, J. R.
Publicado 2010